|
|
|
UroToday GU Onc Today is excited to present the "Leaders in Radiopharmaceuticals: Disruptive Innovations and Personal Perspectives" video series. In this series, A. Oliver Sartor, chair of the Genitourinary Cancer Disease Group and director of Radiopharmaceutical Clinical Trials for the Mayo Clinic Comprehensive Cancer Center, engages with CEOs, CMOs, presidents, and leaders from various theranostic, biotech, and radiopharmaceutical companies. These conversations explore groundbreaking developments in diagnostics and therapy, as well as the companies' current and future development efforts.
|
|
|
|
|
|
|
|
Leaders in Radiopharmaceuticals: Disruptive Innovations and Personal Perspectives |
|
|
|
|
|
| Advancing Radiopharmaceuticals: Isotopes, Targets, and Challenges |
| Germo Gericke, MD |
| Oliver Sartor discusses radiopharmaceuticals with Germo Gericke. Dr. Gericke emphasizes the potential of targeted radioligand therapies, particularly for advanced cancers. He explores various isotopes, including Lutetium, Terbium, and Actinium, highlighting Actinium's promise in preclinical studies. |
|
|
|
|
|
|
|
|
|
|
|
| Copper-67 (Cu-67 or 67Cu) in Cancer Therapy: Current Developments and Future Potential |
| Alan Taylor, PhD |
| Oliver Sartor speaks with Alan Taylor about advances in radiopharmaceuticals for cancer treatment. Dr. Taylor discusses Clarity's focus on copper isotopes, particularly Copper-67 (Cu-67 or 67Cu), for targeted therapy. |
|
|
|
|
|
|
|
|
|
|
|
| Advancing Radiopharmaceuticals: From Lead-212 to Pre-Targeting Strategies |
| Michael Schultz, PhD |
| Oliver Sartor speaks with Michael Schultz about advances in radiopharmaceuticals for cancer treatment. Dr. Schultz discusses the advantages of using alpha-particle emitters, particularly lead-212, for targeted cancer therapy. |
|
|
|
|
|
|
|
|
|
|
|
| Radiopharmaceuticals and Combination Approaches in Advancing the Prostate Cancer Treatment Landscape |
| Philip Kantoff, MD |
| Oliver Sartor speaks with Philip Kantoff about the future of radiopharmaceuticals in cancer treatment. Dr. Kantoff discusses the rationale behind using antibody-based approaches for PSMA-targeted therapies, particularly with actinium-225, citing better cancer cell retention and reduced toxicity to salivary and lacrimal glands compared to small molecules. |
|
|
|
|
|
|
|
|
|
|
|
| Lead-212 Radiopharmaceuticals: Next Frontier in Cancer Treatment |
| Emanuele Ostuni, PhD |
| Oliver Sartor speaks with Emanuele Ostuni about ARTBIO’s focus on radiopharmaceuticals, particularly lead-212. Dr. Ostuni explains ARTBIO’s choice of lead-212 for its short half-life, which better matches the biological half-lives of targeting ligands. |
|
|
|
|
|
|
|
|
|
|
|
| Advancing Radiopharmaceuticals: Targeting Strategies and Isotope Selection in Cancer Therapy |
| John Babich, PhD |
| John Babich discusses the potential of radiopharmaceuticals in cancer treatment. He emphasizes the importance of targeting and retention in tumor tissues, explaining the concept of therapeutic index and the company's "radioligand first, isotope second" approach. |
|
|
|
|
|
|
|
|
|
|
|
| Lead-212 Radiopharmaceuticals: Advancing Targeted Alpha Therapy in Oncology |
| Anna Karmann, MD, PhD |
| Oliver Sartor interviews Anna Karmann about the potential of radiopharmaceuticals in cancer treatment. Dr. Karmann discusses the advantages of Lead-212, highlighting its alpha-emitting properties, short half-life, and potential for frequent dosing strategies. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
